Agenda November, 2025

Continental Breakfast

Open to all attendees

Held in the Conference Hall

An estimated 7.2 million Americans age 65 and older live with Alzheimer’s dementia today. This number could grow to 13.8 million by 2060. Official AD death certificates recorded 120,122 deaths from AD in 2022. Since 2020, when COVID‐19 became one of the top 10 causes of death in the United States, AD has ranked as the seventh‐leading cause of death. However, 2023 data indicate that Alzheimer’s will likely resume its place as the sixth‐leading cause of death. Between 2000 and 2022, deaths from stroke, heart disease, and HIV decreased, whereas reported deaths from AD increased by more than 142%. Nearly 12 million family members and other unpaid caregivers provided an estimated 19.2 billion hours of care to people with Alzheimer’s or other dementias in 2024.

Dr. Rivera will present the fundamentals of cognitive decline, including reversible causes of cognitive decline, and diagnostic formulations like Mild Cognitive Impairment (Mild Neurocognitive Disorder), as well as the most common causes of dementia (Major Neurocognitive Disorder), and their differential diagnoses

While Alzheimer’s disease is the most common form of dementia, it’s not the only cause of cognitive decline. A clinical workup for cognitive decline involves a multi-faceted approach to determine both the severity of impairment and the likely cause or causes.

It’s Not Old Age: The Role of Biotoxins in Cognitive Decline
Mark Sylvester, M.D.
Founder & Chief Medical Officer, Mind Body Medicine of Florida, Sarasota, FL
Founder, Alternative Psychiatry

Cognitive decline is too often dismissed as an inevitable feature of aging, yet emerging evidence demonstrates that environmental biotoxins play a critical role in driving neurodegeneration. Mycotoxins, cyanobacterial toxins, and bacterial endotoxins can trigger chronic neuroinflammation, impair mitochondrial function, and compromise the blood–brain barrier, accelerating processes commonly attributed to “normal aging.” This lecture will explore the mechanistic pathways linking biotoxin exposure to memory loss and dementia, review current research, and highlight functional medicine strategies for assessment, early detection, and targeted intervention to improve cognitive resilience.

Lecture Description TBA

False Facts!

Presented by Mark Hincher, R.Ph., CEO

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Agere Sciences

At least 40% of all dementia has been linked to modifiable risk factors suggesting a clear potential for preventative approaches targeting these factors. Recent research highlights the significant role of multidomain lifestyle interventions in mitigating cognitive decline and preventing the progression to dementia in individuals with Mild Cognitive Impairment (MCI).

Recent research has demonstrated that intensive multimodal lifestyle interventions may improve cognitive function in individuals with MCI or early dementia due to Alzheimer’s disease. Concurrent improvements in biomarkers of Alzheimer’s pathology and biological mechanisms underlying Alzheimer’s disease have also been observed in these approaches.

As there is not one effective treatment to prevent progressive cognitive deterioration, nutritional interventions have been, and still are, one of the most widely explored therapeutic possibilities. There have been many discussions about a great number of potentially interesting plants, nutritional derivatives, and probiotics for the treatment of dementia around the world. Their action mechanisms generally involve neuroprotective effects via anti-inflammatory, antioxidant, anti-apoptotic, β-amyloid, and tau anti-aggregate actions; brain blood flow improvement, and effects on synaptic cholinergic and dopaminergic neurotransmission, which may optimize cognitive performance in patients with cognitive impairment. Hormonal function is also thought to be an important factor in maintaining cognitive function. Neuronal networking is still being researched in regard to the exact pathway for how hormonal changes can directly affect cognitive abilities such as memory, thinking, problem-solving, spatial ability, and even emotion. It not only affects these negatively, but it may also assist as neuro-protectors, as shown by estrogen hormones. Thus, well-maintained hormones throughout life are crucial to support cognitive abilities for both males and females.

Mild to moderate cognitive decline can be reversed with peptides and also with using Therapeutic Plasma Exchange. The large multi-center trial called Ambar using Therapeutic Plasma Exchange in reversing cognitive decline will be reviewed. The data of Cereborlysin will be reviewed. In addition, the addition of using umbilical cord tissue product can also accelerate improvement of cognitive decline. Case studies of reversing cognitive decline will be discussed.

As there is not one effective treatment to prevent progressive cognitive deterioration, nutritional interventions have been, and still are, one of the most widely explored therapeutic possibilities. There have been many discussions about a great number of potentially interesting plants, nutritional derivatives, and probiotics for the treatment of dementia around the world. Their action mechanisms generally involve neuroprotective effects via anti-inflammatory, antioxidant, anti-apoptotic, β-amyloid, and tau anti-aggregate actions; brain blood flow improvement, and effects on synaptic cholinergic and dopaminergic neurotransmission, which may optimize cognitive performance in patients with cognitive impairment. Hormonal function is also thought to be an important factor in maintaining cognitive function. Neuronal networking is still being researched in regard to the exact pathway for how hormonal changes can directly affect cognitive abilities such as memory, thinking, problem-solving, spatial ability, and even emotion. It not only affects these negatively, but it may also assist as neuro-protectors, as shown by estrogen hormones. Thus, well-maintained hormones throughout life are crucial to support cognitive abilities for both males and females.

AMMG Welcome Reception

Open to all conference attendees, spouses and guests

Held in Conference Networking & Events Center

Continental Breakfast

Open to all attendees

Held in the Conference Hall

Breast cancer is the most common cancer diagnosed in women, accounting for more than 1 in 10 new cancer diagnoses each year. It is the second most common cause of death from cancer among women in the world. Breast cancer commonly develops silently, and most of the disease is discovered on routine screening. This interactive seminar will focus on an update on this potentially devastating disease but also one that is very curable or manageable in most patients.

There are several nonmodifiable risk factors for breast cancer that the patient cannot change. This seminar will explore the most common nonmodifiable risk factors for this disease. It is essential that we help patients understand the nonmodifiable risk factors so that they will understand how important it is to control the risk factors that they are able to.

There are several nonmodifiable risk factors for breast cancer that the patient cannot change. This seminar will explore the most common nonmodifiable risk factors for this disease. It is essential that we help patients understand the nonmodifiable risk factors so that they will understand how important it is to control the risk factors that they are able to.

LifespanMedicine has no changed with a personalized approach to health care. This includes breast cancer. There are many modifiable risk factors for the development of this disease along with risk factors that promote a recurrence. This tutorial will examine many of them and discuss what you can do on Monday morning to help the patient change these risk factors.

False Facts!

Presented by Mark Hincher, R.Ph., CEO

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Agere Sciences

False Facts!

Presented by Mark Hincher, R.Ph., CEO

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Agere Sciences

Ice-breaker poll: “How does preventative health or longevity already intersect with AI in your practice?”
Analogy: AI as the “infinite systems analyst” that maps interconnected health variables in real-time.
Workshop objectives: Personalized prevention plans, foresightful healthspan interventions, resilient care ecosystems—all grounded in systems thinking.

1. Problem: Clinicians spend 30%+ of time on fragmented data entry, missing opportunities for preventative pattern recognition across systems (e.g., metabolic, inflammatory, cognitive).
2. Toolbox tour:
• Ambient sensors and wearables for continuous data streams.
• GPT-powered profile builders with systems-oriented prompts (e.g., integrating epigenomic clocks, telomere metrics).
3. Live demo:
• Simulate a 90-sec patient intake (audio + wearable data) → generate a systems health map, preventative risk scores, ICD-10/CPT for wellness visits, and patient-empowering longevity summaries.
4. Micro-exercise:
• Participants customize a prompt to incorporate personal systems lenses (e.g., adding gut-brain axis or stress-resilience factors).
5. Pearls:
• Context windows for longitudinal data, temperature settings for creative yet grounded preventative hypotheses, “systems boundary” lists to control hallucinations.
• Compliance tip: Segregate raw biomarker data from EHR to maintain privacy in preventative tracking.

1. RAG 101: Integrating GPT with trusted longevity sources (e.g., senescence databases, Hallmarks of Aging frameworks).
2. Interactive case:
• Walk through a mid-life patient scenario: AI fuses lifestyle data, labs, and imaging to forecast healthspan trajectories and recommend interventions (e.g., NAD+ boosters, intermittent fasting protocols).
3. Imaging & Biomarkers:
• Vision models for early detection (e.g., retinal scans for vascular aging; AI pattern recognition in multi-omic panels for longevity markers like mTOR activity).
4. Safety levers:
• Chain-of-thought prompting with systems verification + mandatory citations from peer-reviewed longevity studies.
• Double-checking via simulated feedback loops.
5. Take-home prompt skeleton: A template for querying “What interconnected systems risks threaten this patient’s healthspan, and how can we intervene preventatively?”

1. Agents > single prompts: Building adaptive systems that evolve with patient data.
2. Demo build (live coding, 15 min):
• Construct an AI agent that tracks biomarkers, simulates aging trajectories using basic systems models, and automates nudges (e.g., app reminders for senolytic protocols or exercise optimization).
3. Pair-think activity (10 min):
• Groups brainstorm a preventative workflow (e.g., automating annual healthspan check-ins) and prototype an agent prompt.
4. API connectors:
• Integrating with wearables, telehealth platforms, and longevity apps for closed-loop feedback.
5. Guard-rails:
• Ensuring agents respect systems equilibria (e.g., avoiding over-intervention) and flag emergent risks like polypharmacy in anti-aging regimens.

1. Regulatory radar:
• 2. HIPAA for preventative data flows, FDA SaMD tiers for longevity tools, AMA guidelines on AI in wellness/prevention.
2. ROI quick-math:
• 10 min saved per preventative consult × 20 patients/day × 200 days = Y hours/year reclaimed for deeper patient connections; plus quantified healthspan gains (e.g., via VO2 max improvements).
3. Change-management mini-canvas:
• Stakeholders: Clinicians, patients, admins in longevity-focused practices.
• Pilot metric (e.g., adherence rates to preventative plans).
• Feedback loop: Iterative systems audits.
• Scale-up gate: Evidence of enhanced resilience (e.g., reduced chronic disease onset).

1. “Systems-first” checklist:
• Identify one preventative pain-point (e.g., biomarker tracking silos).
• Craft a resilience-focused prompt.
• Launch a micro-pilot with anonymized data.
2. Resource Vault link: Preventative prompt libraries, systems modeling starters, longevity compliance guides.
3. 30-day challenge: Deploy one AI-enhanced preventative strategy and share a 2-minute systems impact video → earn CME credit bonus.
4. Open Q&A in an encouraging, integrative tone—fostering systems curiosity over isolated perfection.

AMMG Welcome Reception

Open to all conference attendees, spouses, and guests

Held in TBA

Brain Aging in Women: Hormones, Cognition, and Implications for Neurodegeneration

Presented by Danielle Osborne, Ph.D.

Open to all attendees and includes a complimentary breakfast

Non-CME symposium sponsored by ZRT Laboratory

I became aware of the works of two independent research physicians as the result of my Covid research for new treatments. Cicero Coimbra, M. D. a Neurologist from Sau Paulo, Brazil’s Medical School, began treatment of his MS patients with gradually increasing doses of Vitamin D and careful monitoring for toxicity. His clinical approach resulted in finding that very high doses of D would slowly put MS cases into 95% remission. Doses ranged from 35,000iu to over 200,000iu daily! The results were sustained in those patients who maintained the treatments for over 15 years in many cases. Other autoimmune diseases were equally responsive. He discovered that there were three groups of responders: low, medium, and high. His work has been replicated in other clinics around the world, but have been under-utilized since it is impossible to do randomized, controlled studies on variable dosing. An independent researcher, Carsten Carlberg M. D. PHD, from Finland, has done research supporting “individualized” Vitamin D dosing for optimal genetic benefits and disease response confirming Coimbra’s observations. I began using the Coimbra Protocol for treatment of Long Covid and had immediate success with careful high dosing. I then used the same approach in a case of chronic Lyme disease, resistant to all antibiotic treatments by her LL physicians for over 20 years. At a treatment pause, she was started on the Coimbra Protocol and saw immediate improvements in pain and inflammation. This led to additional treatments that have continued her successful recovery, now in 95% remission for over 3 years without antibiotics (except acute illness). I now have a growing group of chronic Lyme patients also greatly improved on my new Protocol, that includes the Coimbra Protocol as a core. I believe this new approach can be used in most chronic diseases since vitamin D has so many genes that are affected in these vastly differing diseases. The Protocol is compatible with almost all current treatments so it can be prescribed alone or administered as a co-treatment in most cases. The Protocol is outlined with the supportive literature that explains the success. Conference Attendees will find immediate usefulness in treatment of many chronic diseases in addition to difficult to treat Lyme Disease cases.

Dr. Lawrence will present the results of American and Russian human longevity clinical studies, which focused on the use of Peptide Bioregulators. These natural substances, developed by Prof. Vladimir Khavinson and other Russian scientists, were instrumental in improving longevity biomarkers and reducing all-cause mortality. The results obtained from these studies present compelling evidence that the Telomerase Activation and the Epigenetic Methylation Study protocols, consisting of a complex of Peptide Bioregulators, acted as significant telomerase activators and epigenetic modifying interventions in human subjects. Peptide Bioregulators yield significant gero-protective effects as they lengthen human telomeres, reduce epigenetic all-cause mortality risk, and slow the rate of aging. This outcome confirms Peptides Bioregulators as a significant human biological age intervention via cellular peptide reprogramming interventions, resulting in human tissue rejuvenation and organ regeneration. This research implies that aging itself is no longer a primary determinant of human health and longevity.

Lecture Description TBA

STOP Overpaying Your Taxes and PROTECT your Wealth!

Presented by Joshua Johnson

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by Fortune Law Firm

The science behind women’s hormones, their function and replacement, has been extensively studied over the years. In this seminar Dr. Smith will examine the biochemistry and physiology of women’s hormones, factors that influence each step, along with reasons to consider hormone replacement therapy as the standard of care for all women.

Why do disease-free fully-functioning centenarians consistently show dramatically lower levels of endotoxin compared to ‘healthy’ individuals 60 years younger? The answer reveals one of the most critical yet overlooked drivers of chronic disease and aging:lipopolysaccharides (LPS) — microbial vests designed to protect Gram negative bacteria from the mammals immune system it has infiltrated: silently accumulating in the tissue, eroding health, inflaming the brain, and accelerating decline. Whether your focus is on disease reversal or age optimization, addressing LPS is no longer optional — it is essential. These presentations reveal the science connecting LPS-induced inflammation to nearly every chronic disease and hallmark of aging. From pediatric Alzheimer’s to autoimmunity, from insulin resistance to sepsis, the biological footprint of LPS is both pervasive and insidious. We will address testing and preventive treatment protocols extending ‘Healthy Lifespan’ reducing the pervasive nature of this stealth Disruptor.

Is it controversy or financial interests? Because the manufacturer, Teva Pharmaceuticals discontinued producing mebendazole for (non-safety related) business reasons bendazole was withdrawn from the U.S. market in 2011 until 2016, when it was reintroduced at around 80 times increased price. Depending on who or what you read will dictate your impression of Ivermectin,  mebendazole as a repurposed complimentary cancer treatment. The New York Times, physician at large institutions funded by pharmaceutical companies have traditionally a more negative opinion. They use phrases like “inaccurate comments, misinformation”.  While integrative private physicians and many legislators promote these drugs a complimentary treatment Clinical trials are being set up with a few early in trial. Smaller trials are abundant and flood the journals. None if any are looking at these drugs as solo treatments but as complimentary treatments. One of the mechanisms is by effecting resistant cancer cells. This may be through inhibiting glucose uptake , micro tubular destabilization with resulting apoptosis in cancer cells , specifically. Current studies on going at present and the past. A phase I/II clinical trial at Cedars-Sinai Medical Center, is evaluating ivermectin in combination with balstilimab (an anti-PD-1 checkpoint inhibitor) for metastatic triple-negative breast cancer (TNBC) A phase II clinical trial at Dr. Frank Arguello Cancer Clinic is examining an unconventional therapy approach called atavistic chemotherapy, based on the theory that cancer cells behave similarly to primitive single-celled organisms. 1996, focused on its ability to target P-gp. Specifically, scientists at Strasbourg University, France, demonstrated that ivermectin restored drug retention via P-gp inhibition in multidrug-resistant human leukemia cells. As a result, ivermectin-treated leukemia cells became 60-fold more sensitive to common chemotherapy drugs, such as vinblastine and doxorubicin. More recent studies confirmed that the P-gp inhibitory effect of ivermectin extends beyond leukemia, successfully reversing drug resistance in colorectal, lung and breast cancer cells In a 2021 study, scientists at the Beckman Research Institute, U.S. The study further showed that ivermectin enhanced the efficacy of anti-PD1 therapy (an immune checkpoint inhibitor) in boosting T-cell infiltration and achieving complete tumor regression in a mouse model of immune-evasive breast cancer.

AMMG Exhibit Hall Happy Hour

Join us for complimentary open bar and refreshments

Open to all conference attendees, spouses and guests

Held in Conference Networking and Exhibits Center

Continental Breakfast

Open to all attendees

Held in the Conference Hall

This comprehensive lecture explores the complex interplay between aging and neurodegenerative diseases, highlighting shared cellular and molecular mechanisms that drive both physiological aging and neurological decline. Through a deep dive into Alzheimer’s disease, Parkinson’s disease, ALS, and multiple sclerosis, participants will examine key diagnostic criteria, pathological hallmarks, and the role of protein aggregation and mitochondrial dysfunction. The lecture emphasizes emerging biomarkers, precision medicine approaches, and the impact of genetic and epigenetic factors on disease risk and progression. Attendees will also gain insights into modifiable lifestyle and targeted interventions—ranging from diet and exercise to senolytics and advanced technologies—aimed at promoting neuroprotection, enhancing resilience, and potentially reversing elements of biological aging.

Iron overload—often revealed by elevated ferritin and disrupted hepcidin regulation—is far more prevalent than many clinicians recognize. Beyond its well-known hepatic effects, excess iron/ferritin triggers endocrine dysregulation (notably hypogonadism), metabolic disturbances (including insulin resistance and dysmetabolic syndromes), and systemic health decline. In this session, participants will uncover how iron-related dysfunction contributes to hormonal imbalances, metabolic derangements, and multi-organ risk in both men and women. You’ll learn to interpret iron and ferritin abnormalities thoughtfully, and apply evidence-based strategies for early detection, diagnostic clarity, and comprehensive management.

Lecture Description TBA

This is a powerful discussion of how our current medical system ignores women. The system believes women are done with life at the age of 52. There is a built-in gender-bias that has shaped the health care system and educated generations of physicians. You will learn how for generations women were kept out of medical studies, how men were used in primary studies for uterine cancer, how women were left out of long-term studies on aging, and how the medical system chooses band-aides over prevention in the management of ageing women. This discussion will teach you how to recognize gender bias in medicine and begin to be the solution for decreasing the rate of the top 5 killers of women. You will learn how to transition from this built-in gender bias in the post graduate medical education system to evidence-based, gender-focused care of your female patient.

Title TBA

Presented by TBA

Open to all attendees and includes a complimentary lunch

Non-CME Symposium Sponsored by TBA

As interest in integrative and regenerative approaches to aging grows, the use of low-dose psychedelics, commonly referred to as microdosing, has emerged as a provocative frontier in neuroplasticity enhancement and cognitive wellness. This presentation will explore the current evidence surrounding the use of sub-perceptual doses of psilocybin and ketamine in midlife and older adults, with a focus on their potential to promote neurogenesis, improve mood, enhance executive function, and reduce age-related cognitive decline. Grounded in recent clinical research and supported by translational neuroscience, this session will evaluate the mechanistic basis for psychedelic-assisted neuroplasticity, including the role of BDNF upregulation, serotonergic pathway modulation, and synaptogenesis. In parallel, the talk will address key limitations and risks, including the legal, ethical, and psychophysiological considerations associated with off-label use or self-administered protocols. Special attention will be given to distinguishing between full-dose psychedelic-assisted therapy (e.g., ketamine infusions or psilocybin sessions) and true microdosing regimens, including practical guidance for physicians who may encounter patients already engaging with these interventions. This discussion will emphasize clinical caution while offering a forward-looking perspective on how such tools may eventually integrate with age management protocols aimed at optimizing cognitive longevity, emotional resilience, and overall mental performance in midlife and beyond.

Regulation of the various systems of the body are foundational to the overall health of the individual. Dysregulation can happen from a variety of sources leading to chronic inflammation, micronutrient imbalances, chronic infectious burden, environmental toxicity, and many more factors leading to chronic disease. Regardless of preferred therapy choices, fundamental microcirculation and cellular signaling capacity will be essential in ensuring long term regulation and success –  Longevity. This presentation will review PNEI (Psycho-neuro-endocrine-immunology) with a focus on dysregulation of this system, its effect on GI health and function, and the downstream cellular effects that lead to metabolic dysfunction. Considerations for heavy metal and environmental exposures will be covered and a review of nutritional, emerging, and physical interventions will be covered with a focus on microcirculation, mitochondrial resuscitation, and cell signaling. The regenerative value of treatment synergy will be explored from a multi-treatment intensive perspective with a focus on the value of the Integrative Spa, Wellness Retreat, or Health Resort Medicine model.

Longevity is associated with a unique gut microbiome composition based on multiple clinical and preclinical studies; the patients most studied are Japanese people where centenarians have higher diversity and distinct bacterial and bio-populations compared to others. This microbiome is rich in bacteriophages, which are viruses that can help regulate pathogenic gut bacteria. The data suggests that longevity is associated with a higher microbial diversity of both bacteria and viruses and unique profiles and more microbial genetics that are active related to production of acetate and less production of methane. Proteobacter is negatively associated with longevity, while Bifidobacter, which is a notoriously anti-inflammatory gut bacterial species, is associated with longevity as well. The longevity-promoting microbiome is also associated with more abundant in complex carbohydrate metabolism. Treatments such as vagus nerve stimulation, probiotics, prebiotics, and polyphenols will be discussed for their clinical utility.

Erectile dysfunction (ED) is a common and often multifactorial condition that significantly impacts quality of life for aging men. This lecture presents a practical, evidence-informed approach to evaluating and managing ED, emphasizing both foundational therapies and novel interventions. Attendees will learn how to address underlying lifestyle factors, optimize hormone levels, and incorporate standard treatments such as PDE5 inhibitors. The presentation will also explore emerging modalities including vacuum erection devices as preventative tools, platelet-rich plasma (PRP) injections, low-intensity shockwave therapy, and experimental uses of botulinum toxin. Clinical pearls, case-based discussion, and practical implementation strategies will equip providers to broaden their therapeutic toolkit and better support patients dealing with ED.

Continental Breakfast

Open to all attendees

Held in the Conference Hall

Traditional laboratory medicine focuses on population reference ranges, whose broad statistical boundaries often obscure early dysfunction. The Laboratory of Functional Medicine reconceptualizes routine and specialized assays by anchoring interpretation at physiologic medians and combining them with organ-specific calculations, revealing pathological trends years before clinical thresholds are crossed. The lecture covers the endocrine, cardiometabolic, immunologic, and gastrointestinal domains of functional medicine. It demonstrates how recalibrated metrics—such as the thyroid fT3/rT3 proxy, an insulin-resistance index, Lp-PLA2 and MPO gradients, and the ESR-CRP-LDH composite—correlate with distinct pathophysiologic pathways. Case vignettes where targeted therapy normalizes values and reverses symptoms are used as examples. Beyond serum, multi-matrix testing is showcased: four-point salivary cortisol, hydrogen–methane breath analysis for SIBO, qPCR stool profiling with zonulin permeability markers, and micronutrient panels that expose subclinical deficits. Algorithms integrate data into evidence-based nutritional, lifestyle, and pharmacologic interventions. Specific thresholds, for example, Lp-PLA2 < 200 U/L, ferritin 90–110 ng/mL, zonulin < 50 ng/mL, are correlated with symptom resolution, underscoring the laboratory’s role as a navigational dashboard for precision care. Ultimately, aligning analytical precision with functional insight, this lecture equips laboratory physicians to transform static data into dynamic clinical guidance, advancing preventive strategies, refining risk stratification, and fostering collaborative, personalised care across chronic endocrine, cardiovascular, and inflammatory disorders. The framework is scalable for hospital laboratories and point-of-care networks globally.

Practitioners in age management know that increasing energy, gaining muscle and losing fat are common client goals. Most also know that DEXA scanning is the best way to measure body fat and muscle, and that VO2 testing is the best way to assess not only cardiovascular fitness, but also metabolic rate and mitochondrial effectiveness. But many may not know how indispensable DEXA scanning and VO2 testing can be toward the success of their clients and their practices. Through a combination of didactic instruction and case examples, participants will learn (1) how DEXA scanning and VO2 testing work, (2) how to interpret test results and use them to improve diagnosis, treatment and results, and (3) what the best options are for incorporating them into age management practices, including not only protocols for clinical care, but also staffing and other operational implications.

Migraine is a complex neurovascular disorder influenced by genetic, environmental, and biochemical factors. Emerging evidence suggests that impaired detoxification pathways—particularly those involving mitochondrial function, oxidative stress, and methylation—may significantly contribute to the pathophysiology of migraine. This presentation explores the role of genomic and nutrient-based interventions to optimize detoxification and mitochondrial metabolic pathways in individuals with migraines.  Through the lens of functional medicine and precision genomics, we will examine key polymorphisms in detox-related genes (e.g., MTHFR, COMT, GPX, G6P, SOD2), discuss nutrient cofactor deficiencies that impair enzymatic function, and review data linking mitochondrial dysfunction with migraine severity and frequency. Nutritional and lifestyle interventions—including targeted supplementation with riboflavin, magnesium, CoQ10, and methyl donors—will be presented as viable adjunctive strategies. Case examples will highlight how personalized genomic data can inform tailored detoxification support to reduce migraine burden.